Original ContributionArsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB 99903)
References (13)
- et al.
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
Blood
(1999) Optimal two-stage designs for phase II clinical trials
Control Clin Trials
(1989)- et al.
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
J Clin Oncol
(2000) - et al.
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study
J Clin Oncol
(1997) - et al.
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies
Curr Opin Hematol
(2005) - et al.
Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells
Leukemia
(2003)
There are more references available in the full text version of this article.
Cited by (7)
LncRNA OTUD6B-AS1 Exacerbates As<inf>2</inf>O<inf>3</inf>-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2
2020, Oxidative Medicine and Cellular LongevityThe crosstalk between trace elements with DNA damage response, repair, and oxidative stress in cancer
2019, Journal of Cellular BiochemistryChronic arsenic intoxication diagnostic score (CAsIDS)
2018, Journal of Applied ToxicologyThe potential role of arsenic trioxide in the treatment of iodine non-avid thyroid cancer
2014, Horizons in Cancer ResearchSecond-line systemic therapy for metastatic urothelial carcinoma of the bladder
2013, Future Oncology
This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA.
Electronic forwarding or copying is a violation of US and international copyright laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1558-7673, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.
Copyright © 2009 Elsevier Inc. All rights reserved.